JP2021522795A5 - - Google Patents

Info

Publication number
JP2021522795A5
JP2021522795A5 JP2020561780A JP2020561780A JP2021522795A5 JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5 JP 2020561780 A JP2020561780 A JP 2020561780A JP 2020561780 A JP2020561780 A JP 2020561780A JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5
Authority
JP
Japan
Prior art keywords
amino acid
sequence
item
acid sequence
seq
Prior art date
Application number
JP2020561780A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019213446A5 (https=
JP2021522795A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030475 external-priority patent/WO2019213446A1/en
Publication of JP2021522795A publication Critical patent/JP2021522795A/ja
Publication of JP2021522795A5 publication Critical patent/JP2021522795A5/ja
Publication of JPWO2019213446A5 publication Critical patent/JPWO2019213446A5/ja
Pending legal-status Critical Current

Links

JP2020561780A 2018-05-03 2019-05-02 TGFβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 Pending JP2021522795A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666548P 2018-05-03 2018-05-03
US62/666,548 2018-05-03
US201862779992P 2018-12-14 2018-12-14
US62/779,992 2018-12-14
PCT/US2019/030475 WO2019213446A1 (en) 2018-05-03 2019-05-02 NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2021522795A JP2021522795A (ja) 2021-09-02
JP2021522795A5 true JP2021522795A5 (https=) 2022-05-13
JPWO2019213446A5 JPWO2019213446A5 (https=) 2022-05-13

Family

ID=68386156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561780A Pending JP2021522795A (ja) 2018-05-03 2019-05-02 TGFβ−スーパーファミリーのリガンドの新規バインダーおよびその使用

Country Status (6)

Country Link
US (2) US12168683B2 (https=)
EP (1) EP3788067A4 (https=)
JP (1) JP2021522795A (https=)
AU (1) AU2019262143A1 (https=)
CA (1) CA3099325A1 (https=)
WO (1) WO2019213446A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213442A1 (en) 2018-05-03 2019-11-07 Acceleron Pharma Inc. MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
WO2021092079A1 (en) 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof
WO2023049917A1 (en) * 2021-09-27 2023-03-30 Zoetis Services Llc ANTI- TGFβ1,2,3 ANTIBODIES AND THERAPEUTIC USES THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
CA3083324A1 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
NZ707477A (en) * 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
JP6631865B2 (ja) * 2014-08-11 2020-01-15 日本化薬株式会社 TGFβ阻害機能を持つキメラタンパク質
US10227392B2 (en) * 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントActRIIBタンパク質およびその使用
US11440949B2 (en) 2016-10-05 2022-09-13 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
BR112019006993A2 (pt) 2016-10-05 2019-09-03 Acceleron Pharma Inc heteromultímeros de alk4:actriib e usos dos mesmos

Similar Documents

Publication Publication Date Title
JP2021522795A5 (https=)
EP3218411B1 (en) Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
US20230348565A1 (en) Methods of using activin receptor type ii variants
JP2021175391A5 (https=)
CN119569850A (zh) 激活素受体iia型变体及其使用方法
CN106687478A (zh) 新的抗人Tie‑2抗体
JP2021522793A5 (https=)
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
CN119032104A (zh) 抗血清白蛋白纳米抗体及其衍生物
US20180280474A1 (en) Treatment of bile acid disorders
JPWO2020173897A5 (https=)
JPWO2019213446A5 (https=)
JPWO2019213442A5 (https=)
WO2024017281A1 (zh) 多特异性抗体及其用途
CN117295758A (zh) 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白
WO2022226352A1 (en) Kidney-glomerular targeted immunotherapy
JPWO2022150788A5 (https=)
AU2022316521B2 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
WO2025228408A1 (zh) Ghr激动型抗体及其应用
TW202342551A (zh) 包含抗原結合結構域及細胞因數三聚體結構域的融合蛋白
CN118119402A (zh) 工程化抗her2双特异性蛋白
CN121517537A (zh) 一种阻断baff、april作用其受体的融合蛋白
CA3196077A1 (en) Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
JP2025524899A (ja) メソテリン結合タンパク質及びその使用
HK40092774A (zh) 使用激活素受体ii型变体的方法